AstraZeneca's drug headache leads to profits slump
The emptiness of AstraZeneca's drug cabinet was laid bare yesterday as a number of patent expiries – including its bestselling cholesterol-buster Crestor – saw the pharmaceutical giant miss City expectations on sales and profits, both of which fell for the seventh-consecutive quarter.
AstraZeneca's pre-tax profits slumped 24 per cent to $4bn (£3.4bn) during the first nine months of the year. News that the struggling drug maker has appointed a new finance boss – ex-GlaxoSmithKline executive Marc Dunoyer will take over from the departing Simon Lowth – could not stop its shares falling 21p to 3,309p.
Mr Dunoyer, currently AstraZeneca's head of product development, joined the company from GSK over the summer.
AstraZeneca admitted that cheaper, generic rivals on several brands including ulcer treatment Nexium and anti-psychotic Seroquel IR, as well as Crestor in Canada and Australia, had knocked $350m off its revenues in just the last three months. That was, however, a lower hit than experienced in each of the previous four quarters.Overall, sales slumped 9 per cent to $18.9bn between January and September. The negative impact of US healthcare reform also cost AstraZeneca – the hit was $199m in just the last three months.
One glimmer of good news was that the drug maker managed to grow sales in China, where other pharma giants, including AstraZeneca's domestic rival GSK, stand accused of a bribery scandal.
The company's growth in the country was "slower" at 13 per cent, it said, but that compared to GSK Chinese sales crashing by 61 per cent in the third quarter.
AstraZeneca's chief executive, Pascal Soriot, who has been in the job for just over a year, claimed he was "pleased with the progress we are making, particularly on the pipeline".
AstraZeneca has seen three regulatory filings and three drugs begin Phase III trials in recent months – but has also been hit by a string of hoped-for breakthrough drugs failing at trials this year.
Mr Soriot has presided over thousands of job cuts, particularly in sales, cutting the company's headcount by more than 11,000 over two years.
- 1 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 2 Kim Kardashian on Bruce Jenner's 'story': 'We support him no matter what, and I think when the time is right, he'll talk'
- 3 Russian girl takes her own life after parents find pornography on her computer
- 4 Ball pool for adults opens in London
- 5 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Kim Kardashian on Bruce Jenner's 'story': 'We support him no matter what, and I think when the time is right, he'll talk'
Michelle Obama highlights harsh restrictions faced by Saudi women after meeting King Salman without wearing a headscarf
Russian girl takes her own life after parents find pornography on her computer
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British Muslim school children suffering a backlash of abuse following Paris attacks
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
iJobs Money & Business
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...
Competitive salary & benefits!: MBDA UK Ltd: MBDA UK LTD Indirect Procurement...